New PBS drug will mean better outcomes for families
A drug used to treat a rare form of Hodgkin lymphoma is now widely available through the national Pharmaceutical Benefits Scheme (PBS), saving families thousands of dollars.
The PBS listing of brentuximab vedotin gives Australians access to a potentially life-saving treatment that previously cost up to $16,100 for a single course.
The Leukaemia Foundation presented comprehensive consumer submissions to assist the Pharmaceutical Benefits Advisory Committee (PBAC) in its consideration of the applications for brentuximab vedotin.
The submissions contained information from two Leukaemia Foundation surveys about the quality of life among those Australians living with relapsed or refractory Hodgkin lymphoma.
Leukaemia Foundation CEO, Bill Petch, said listing brentuximab vedotin on the PBS ensures equal access to the life-saving treatment for all Australians who require it.
“Together we can help elevate the vital needs of people impacted by a blood cancer diagnosis and achieve better outcomes for more Australian families.”
Brentuximab vedotin will help people with relapsed or refractory CD30 + Hodgkin lymphoma following autologous stem cell transplant (ASCT), and patients with relapsed or refractory CD30 + Hodgkin lymphoma following at least two prior therapies when ASCT or multi-agent chemotherapy was not a treatment option.